GlassScriptPhysician profile
Ashley M Bogue
NPI 1538543368
$2,800.86
in general payments reported to CMS, 2019-2025
22 companies · $1,753 in 2025
The $1,753 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $46.24 · 2024: $1,001 · 2025: $1,753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,755 · Education: $46.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,754.62 |
| Education | $46.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $372.68 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $367.63 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $307.68 | 2024-2025 | Caplyta |
| Pfizer INC. | $284.42 | 2024-2025 | |
| Abbvie INC. | $262.96 | 2024-2025 | |
| Novo Nordisk INC | $248.57 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $199.89 | 2024-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $136.59 | 2024-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $95.02 | 2024-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.82 | 2024-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.81 | 2024-2025 | Xifaxan |
| Daiichi Sankyo INC. | $71.17 | 2024 | Injectafer |
| Merck Sharp & Dohme LLC | $66.28 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Phathom Pharmaceuticals, INC. | $60.96 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $34.12 | 2024 | Trintellix |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $32.68 | 2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $26.21 | 2025 | |
| Lundbeck LLC | $21.01 | 2025 | Rexulti |
| Biogen, INC. | $20.68 | 2025 | Skyclarys |
| Novartis Pharmaceuticals Corporation | $19.57 | 2025 | |
| Astellas Pharma US INC | $13.33 | 2024 | Veozah |
| Echosens North America, INC. | $11.78 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Bogue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.